Treatment of aGVHD with OKT3: Clinical outcome and side-effects associated with release of TNFα

B. Gleixner, H. J. Kolb, E. Holler, S. Liesenfeld, C. Riedner, E. Hiller, C. Seeber, J. Kempeni, A. Moller, H. Knabe, W. Mempel, G. Ledderose, W. Wilmanns

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Monoclonal antibodies are increasingly used for treatment of acute graft-versus-host disease (aGVHD) in bone marrow transplantation. We treated seven patients with steroid resistant aGVHD with the monoclonal anti-T cell antibody OKT3. Though five patients showed improvement of aGVHD, only two became long-term survivors. OKT3 treatment was accompanied by deterioration of microangiopathy and prolonged increase of tumor-necrosis-factor alpha serum levels indicating activation of monocytes/macrophages in vivo, as this was not observed in a control group of patients receiving anti-T cell globulin. These findings may be related to immunostimulatory activity reported for OKT3 in vitro. Strategies interfering with cytokine release should improve clinical results of OKT3 treatment.

Original languageEnglish
Pages (from-to)93-98
Number of pages6
JournalBone Marrow Transplantation
Volume8
Issue number2
StatePublished - 1991
Externally publishedYes

Fingerprint

Dive into the research topics of 'Treatment of aGVHD with OKT3: Clinical outcome and side-effects associated with release of TNFα'. Together they form a unique fingerprint.

Cite this